{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2"},{"groupId":"OG001","value":"42.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.","groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed and best supportive care","id":"OG000","title":"Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed + cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Baseline to date of measured progressive disease (up to 19.3 months)","title":"Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off","type":"SECONDARY","unitOfMeasure":"percentage of participants"}